Bromantane
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
A slow-onset motivation and fatigue tool for people who want dopaminergic drive without the jitter, crash, or appetite suppression of classic stimulants.
The safety job is interaction screening: hormonal contraception, SSRIs, antiepileptics, pregnancy, and drug-tested sport matter more than stimulant-style crash management.
A slow-onset motivation and fatigue tool for people who want dopaminergic drive without the jitter, crash, or appetite suppression of classic stimulants.
Main watch items are CYP3A4 induction that can reduce hormonal contraceptive, SSRI, and antiepileptic exposure, WADA S6 prohibition, and pregnancy contraindication.
Bromantane offers motivation and fatigue reduction without the usual stimulant crash, appetite suppression, or dependency profile, and some users report benefits that persist after stopping.
Variable: many users report calmer task initiation after 1–2 weeks, while a meaningful minority find it mild or underwhelming. Poor absorption from fasted dosing appears to explain part of the split.
Intro
Bromantane (commercially sold in Russia as Ladasten) is a synthetic adamantane derivative developed in the Soviet Union during the 1970s–1980s at the Institute of Medicinal Chemistry in Moscow.
It was designed as part of the Soviet actoprotector program — a class of compounds intended to enhance physical and mental work capacity in soldiers and extreme-condition workers without the dependency, cardiovascular burden, or crash of amphetamines. The compound gained international attention primarily through the 1996 Atlanta Olympics, where multiple Russian athletes tested positive; it was undetectable via standard urine testing at the time and required blood testing for identification. WADA subsequently banned it under S6 (Non-Specified Stimulants), where it sits alongside amphetamines, adrafinil, and cocaine.
Bromantane's mechanism is fundamentally different from conventional stimulants: it upregulates tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) — the rate-limiting enzymes in dopamine biosynthesis — via epigenetic demethylation of the TH gene promoter region. Rather than forcing dopamine release from existing stores or blocking its reuptake, bromantane expands the brain's capacity to manufacture dopamine. Russian research demonstrated that a single dose caused CpG island demethylation in the rat hypothalamus, producing a >2-fold increase in TH mRNA. The compound also exhibits anxiolytic properties likely via serotonergic modulation, and does not increase oxygen consumption or body temperature — defining features of the actoprotector class that distinguish it from classic stimulants.
Regulatory status: approved in Russia as Ladasten for neurasthenia and asthenic disorders; not FDA-approved in the US; not a scheduled substance in most Western markets (sold as research chemical or supplement). UK price approximately £1/100mg. WADA ban applies to all tested athletes.
Observed Effects
Human data is anchored to two primary sources: a Russian clinical trial of 728 patients diagnosed with neurasthenia/asthenia (28-day course) achieving a 90.8% positive response rate, with benefits persisting in many patients for up to one month after cessation — a post-cessation durability pattern not demonstrated for any conventional stimulant. A separate study in 10 healthy human volunteers confirmed measurable subjective and objective changes in mental state, though full data remains behind a paywall.
Animal data is more robust. Physical work capacity studies showed 0.5–50 mg/kg improved swimming and treadmill performance in mice and rats by 1.3–1.6× compared to amphetamine at optimal doses, with effects lasting at least 24 hours. A pharmacological spectrum study confirmed strain-dependent responses: anxiolytic effect in BALB/c mice (prevented freezing in open field test), stimulatory effect in C57B1/6 mice. This genetic phenotype variation is the proposed explanation for inter-individual response variability in humans. Rectal temperature decreased 0.5–1°C at virtually all doses, confirming the actoprotector non-thermogenic property. Animal mitochondrial studies showed prevention of cardiomyocyte and skeletal muscle ultrastructural damage under extreme exercise loads.
Community reports describe the dominant subjective experience as motivational rather than stimulatory — users feel more inclined to begin tasks without jitteriness, elevated heart rate, or appetite suppression. The onset is consistently described as gradual (7–14 days), consistent with enzyme upregulation kinetics rather than receptor binding. Progressive normalization of energy and motivation, improved verbal fluency, and mood stabilization are the most commonly reported benefits. A meaningful non-responder minority reports only mild stimulation or anxiolysis rather than a modafinil-like cognitive boost.
Field Reports
Positive field reports describe progressive improvement in motivation, verbal fluency, and mood over 2–4 week periods.
Common language: 'less mental friction to start tasks,' 'motivation feels effortless rather than forced,' 'subtle but cumulative.' It is particularly valued by users transitioning away from amphetamine-class stimulants who notice the absence of jitteriness, crash, and appetite suppression.
The most important counterpoint is a named-user negative account from 2024: purchased bromantane in the UK at approximately £1/100mg and found it mostly disappointing, mildly stimulating at best, and nothing like modafinil. This represents the honest underwhelming experience that a meaningful minority of users report, and it matters because it matches the broader non-responder pattern rather than isolated anonymous noise.
A cross-community pattern holds: the anxiolytic component appears more consistently reported than the stimulatory component. Multiple users describe feeling calmer and less socially anxious even when they do not notice obvious energy enhancement. The motivational phenotype is distinct from stimulation: 'not wired but not tired' captures the most common positive description.
Key practical learnings from community: non-responders should try fat co-administration before concluding it does not work; expect no day-1 effect because the mechanism is slow; morning dosing is essential; the anxiolytic effect often appears before the motivational effect.
Community Consensus
Bromantane's community reputation is shaped by two distinct narratives: the Soviet actoprotector science (military, athletic performance, neurasthenia treatment) and the 1996 Olympics doping scandal that brought it to Western awareness. In the West, it circulates primarily in nootropic and biohacking communities as an atypical dopamine optimizer — less well-known than modafinil or racetams, but appreciated by users who find conventional stimulants too stimulating or too crash-prone.
The community has coalesced around a consistent characterization: bromantane is motivational rather than stimulatory, anxiolytic rather than anxiogenic, slow-onset rather than immediate. The non-responder phenomenon is well-documented and attributed primarily to inadequate fat co-administration. Nootropic writers and practitioner communities tend to frame it as more than a generic dopamine booster because of the CpG demethylation mechanism, but it remains a niche compound that many users encounter through stack discussions rather than as a primary research target.
Primary use communities: knowledge workers seeking sustainable motivation without stimulant crash; people with chronic fatigue or neurasthenia; individuals with social anxiety who find dopaminergic support helpful; users in stimulant tolerance cycles; biohackers interested in epigenetic modulation. Limited Western clinical data is the primary criticism: the evidence base is largely Russian animal studies and one large clinical trial (728 patients) not accessible in English peer-reviewed literature in a format available for meta-analysis.
Risks & Monitoring
At typical doses (25–50mg), bromantane is generally well-tolerated with no documented withdrawal syndrome in community use.
Sleep interference is possible at 50mg+ if taken in the afternoon or evening — morning dosing is community consensus. One low-certainty report associated bromantane in a complex multi-compound nootropic stack with impulsive decision-making behavior (certainty 0.6; likely reflects the full stack rather than bromantane alone).
The most clinically significant concern is CYP3A4 induction, which is underappreciated in community discussions. Bromantane induces this major metabolic enzyme, accelerating degradation of drugs that use this pathway: hormonal contraceptives (reduced contraceptive efficacy — backup contraception required), some SSRIs (reduced plasma levels and therapeutic effect), antiepileptics (reduced plasma levels, increased seizure risk), and some statins. Any user on CYP3A4-dependent medications requires medical supervision before starting bromantane.
At toxic doses in animals: at 300–600 mg/kg (far above any human dose range), bromantane suppressed motor activity, reduced pain sensitivity, and caused mydriasis; gastrointestinal effects at very high doses. LD50 data not accessible in available abstracts but toxicity in rodent studies appears modest at doses relevant to human use translation.
Populations to avoid use: WADA-tested athletes (S6 ban); pregnancy (high-dose reproductive rat study conducted, human data absent); users on hormonal contraceptives without backup contraception or physician consultation.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Bromantane's CYP3A4 induction is the primary safety gate. Users must review all current medications for CYP3A4 dependence before starting. No blood panel is required for the compound itself at typical doses, but the drug interaction check is non-negotiable.
Long-term CYP3A4 induction could theoretically affect liver enzyme levels; baseline is prudent for extended use (8+ weeks). No reported hepatotoxicity in community use, but data is sparse.
Given the gradual onset, weekly subjective scoring helps users detect whether the compound is working and prevents day-1 non-response from being mistaken for failure. This is useful outcome tracking, not a safety gate.
This becomes a required safety step for users relying on hormonal contraception. CYP3A4 induction may reduce contraceptive efficacy, so backup contraception or alternative methods should be discussed with a physician before starting bromantane.
Avoid With
Do not combine Bromantane with the following. Sorted highest-severity first.
Why:CYP3A4 induction reduces circulating levels of synthetic estrogens and progestins, potentially reducing contraceptive efficacy.
What to do:Backup contraception required; physician consultation essential.
Why:CYP3A4 induction may reduce plasma levels of some antiepileptics, increasing seizure risk.
What to do:Antiepileptic levels may require monitoring if bromantane is used concurrently.
Why:CYP3A4 induction accelerates SSRI metabolism, potentially reducing plasma levels and therapeutic effect.
What to do:Not all SSRIs are significantly CYP3A4-dependent; consult a pharmacist for specific interactions.
Why:Both compounds upregulate tyrosine hydroxylase (bromantane via epigenetic demethylation; 9-Me-BC via MAO-B inhibition and neurogenesis), creating redundant dopaminergic load with poorly characterized additive effects.
What to do:Community considers stacking these redundant or potentially overstimulatory. No safety data on the combination.
Why:Compounded dopaminergic stimulation with no characterization of additive or synergistic risk profile.
What to do:Bromantane can be used to transition away from conventional stimulants, not typically alongside them.
Protocols By Goal
Cognitive performance / knowledge work: 25–50mg morning with fatty meal. Common additions: Uridine 150–250mg, L-Theanine 100–200mg, CDP-Choline 250mg.
Picamilon (20–50mg) cited in community as taking the edge off any stimulatory component for anxious users. Cycle 4–6 weeks on, 2–4 weeks off.
Chronic fatigue / asthenia: 25–50mg morning with minimal additional stack — evaluate response to bromantane alone first given the slow onset and the need to isolate the compound's effect. 28-day course aligned with the Russian asthenia trial. Allow at least 2 weeks before judging effectiveness.
Mood and social anxiety: 25mg morning. L-Theanine or magnesium glycinate as anxiolytic support if needed. The dual anxiolytic + motivational mechanism makes it appealing for users with avoidance behavior driven by anxiety and low motivation simultaneously. 4–6 week cycles.
Stimulant cycle break: 25–50mg morning for users tapering or cycling off amphetamines or modafinil to allow receptor recovery. Bromantane's different mechanism (production expansion vs. release/reuptake) may partially maintain function during conventional stimulant wash-out. Not a substitute for medical guidance during stimulant discontinuation.
Dosing Details
Standard community dose: 25–50mg oral, taken in the morning with a fatty meal. Starting dose for first-time users: 10–25mg to assess tolerance and response.
Upper range: 50–100mg occasionally reported, though no clear benefit data above 50mg exists and sleep interference risk increases.
Fat co-administration is critical — not optional for many users. Bromantane is highly lipophilic, and absorption is strongly food-dependent. Taking with avocado, olive oil, fatty fish, MCT oil, or full-fat dairy meaningfully improves bioavailability. Non-responders who took it fasted should retry with fat before concluding the compound is ineffective.
Onset expectation: no meaningful day-1 effect. Subtle changes may begin within 3–5 days; clearer effects often emerge at 7–14 days. Full enzyme upregulation may take 2–4 weeks. Community practitioners using it personally confirmed the 25mg dose range.
Typical cycling: 4–8 weeks continuous use, followed by 2–4 weeks off. The Russian asthenia clinical trial used a 28-day continuous course. Post-cessation durability suggests cycled use may be as effective as continuous use.
Stacks & Alternatives
Verbal fluency and cognitive performance stack. Uridine supports dopamine receptor sensitivity; CDP-Choline provides acetylcholine substrate; L-Theanine smooths the stimulatory edge. Referenced in community discussions around nootropics for verbal fluency.
Anxiolytic complement stack. Picamilon (GABA agonist) takes the edge off any stimulatory effects while both contribute to reduced anxiety and improved verbal fluency. Sourced from community nootropic stack discussions.
Mitochondrial and cognitive performance stack. Bromantane addresses dopaminergic motivation; NMN addresses energy metabolism. Keto diet context may improve bromantane bioavailability via increased dietary fat intake.
Alternatives
Stack Cost
Moderate stack tax: bromantane is light on labs and physical burden, but it spends real capacity on CYP3A4 medication screening, stimulant-stack restraint, slow-onset expectation management, and WADA/pregnancy exclusions.
The article repeatedly identifies CYP3A4 induction as bromantane's primary safety gate, with possible loss of efficacy for hormonal contraceptives, some SSRIs, antiepileptics, and statins. That makes medication review the dominant stack constraint.
Bromantane is framed as motivational rather than amphetamine-like, but the article still flags sleep interference at 50mg+ or afternoon dosing and cautions against redundant dopaminergic stacking with 9-Me-BC, amphetamines, or modafinil.
The recommendedPanels section does not require intensive bloodwork for typical use; it mainly requires medication review, optional baseline liver enzymes for extended runs, contraceptive efficacy assessment, and weekly subjective tracking.
womenConsiderations marks pregnancy contraindicated and highlights hormonal-contraceptive interaction risk, while also stating no direct HPG-axis suppression or menstrual disruption is expected.
The article describes bromantane as inexpensive relative to many nootropics and available through nootropic/research channels, though it remains outside FDA-approved Western medicine and depends on research-chemical quality.
- ·Treat CYP3A4 screening as mandatory before use; bromantane should not be added casually to stacks containing hormonal contraceptives, antiepileptics, CYP3A4-reliant SSRIs, or other concentration-sensitive medications.
- ·Use it as the dopaminergic motivation layer, not as an add-on to every stimulant; concurrent amphetamines, modafinil, and 9-Me-BC are already listed as caution conflicts.
- ·Keep dosing in the morning and judge response over a 7-14 day onset window; do not escalate quickly because day-1 effects are subtle or absent.
- ·For women using hormonal birth control, the stack is not capacity-neutral unless backup contraception or physician-guided contraception planning is in place.
- ·Do not use in WADA-tested settings regardless of how subtle the subjective effect feels.
- ·Baseline medication review focused on CYP3A4 metabolism and concentration-sensitive drugs.
- ·Backup contraception planning for users relying on hormonal contraceptives.
- ·Morning-only dosing and sleep tracking if dose approaches or exceeds 50mg.
- ·Fat-containing meal co-administration to reduce false non-response from poor absorption.
- ·Weekly energy, mood, and motivation scoring so the slow onset is evaluated deliberately.
The article's own quickSummary calls bromantane intermediate because it requires patience, fat co-administration, and medication-interaction assessment. It is not a high-lab compound, but the CYP3A4 and WADA constraints make casual first-stack use inappropriate for some users.
- ·Using hormonal contraceptives without backup contraception planning
- ·Taking antiepileptics or other concentration-sensitive medications
- ·Subject to WADA or similar anti-doping rules
- ·Expecting an amphetamine-like same-day stimulant effect
The article reports no withdrawal syndrome in community use and emphasizes post-cessation durability rather than rebound. Off-ramping is mostly stopping and allowing the slow-onset effect to fade, while accounting for any interacting medications.
- ·Loss of motivational benefit after the durability window
- ·Difficulty distinguishing true non-response from poor absorption or too-short trial
- ·Need to reassess affected medications or contraception timing if bromantane was inducing CYP3A4
Make the CYP3A4 medication review the first gate. If a user is on a concentration-sensitive medication, treat bromantane as physician-supervised rather than a casual nootropic.
Set the expectation that enzyme upregulation is gradual, use morning dosing, and track response weekly rather than chasing an acute stimulant hit.
Use bromantane as the primary dopaminergic layer during the test period. The article already frames 9-Me-BC and conventional stimulants as caution conflicts.
Repeat assessment with a fat-containing meal and a 7-14 day trial window before classifying the user as a non-responder.
The article treats CYP3A4 induction and reduced contraceptive efficacy as the most important women-specific safety issue.
The article warns that CYP3A4 induction may reduce levels of affected antiepileptics and increase seizure risk.
womenConsiderations marks pregnancy contraindicated and notes absent human reproductive safety data.
The article states bromantane is WADA-banned under S6.
Practical Setup
Fat co-administration is critical — not optional for many users. Bromantane's high lipophilicity means absorption is strongly food-dependent.
Taking with a fat-containing meal (avocado, olive oil, eggs with butter, fatty fish) versus fasted can dramatically alter the effective dose. This is the primary explanation for the non-responder phenomenon and should be the first intervention tried before concluding the compound is ineffective.
The most common reason users abandon bromantane prematurely is expectation mismatch — expecting amphetamine-like stimulation on day 1 and finding nothing. Communicating that enzyme upregulation takes 7–14 days to manifest and that this timeline is mechanistically expected (not a product quality issue) is essential to accurate self-assessment.
CYP3A4 induction is the most underappreciated practical safety consideration. Any user on medications — especially hormonal contraceptives, SSRIs, or antiepileptics — must evaluate CYP3A4 interaction before using bromantane. This is not a theoretical concern: the induction is well-characterized and the drug classes affected have clinically meaningful concentration dependence.
Post-cessation durability (benefits lingering 4 weeks after a 28-day course) supports cycled use as equally effective to continuous use, and avoids any theoretical long-term adaptation.
WADA S6 ban is definitive. Any athlete subject to drug testing must not use bromantane regardless of the expected testing window — bromantane's detection window is not well-characterized in the community.
Sourcing: quality varies in the research-chemical and nootropic market. Third-party certificate of analysis (CoA) for purity is strongly recommended for powder purchases.
Mechanism Deep Dive
Bromantane's primary mechanism is tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) upregulation via epigenetic demethylation of the TH gene promoter.
Russian research demonstrated that a single dose caused demethylation of CpG islands in the rat hypothalamus TH gene promoter region, producing a >2-fold increase in TH mRNA. TH is the rate-limiting enzyme in dopamine biosynthesis — increasing its expression expands the brain's dopamine production capacity without forcing release from existing stores or blocking reuptake. This is the fundamental mechanistic distinction from amphetamines (release), cocaine/NDRIs (reuptake blockade), and MAOIs (degradation inhibition).
The CpG island demethylation is the most distinctive pharmacological feature. Methyl groups on the TH gene promoter act as transcriptional silencers; bromantane removes them, exposing CREB and AP2 binding sites and enabling higher TH expression. This is a change in gene accessibility — explaining why the effect is durable and why benefits persist weeks after cessation. The effect builds over days rather than occurring at receptor binding speeds.
Secondary mechanisms include: serotonergic modulation (anxiolytic effect via serotonin receptor activity, mechanism not fully characterized); membrane-protective effect (prevention of mitochondrial damage in cardiomyocytes and skeletal muscle under extreme exercise loads); sympathoadrenal dampening (reduced urinary catecholamine excretion in freely moving rats, explaining the absence of cardiovascular stimulant side effects); and n-cholinolytic activity (documented at 30 mg/kg in rats, more pronounced than at 600 mg/kg, may contribute to mydriasis at high doses).
Bromantane's adamantane scaffold (the same cage structure as amantadine and memantine) provides the lipophilicity enabling blood-brain barrier penetration and explains the fat co-administration requirement. The para-bromophenyl group contributes the pharmacologically active portion. Structural relatives (adapromine, midantane) show different EEG profiles, indicating mechanism-relevant structural specificity. CYP3A4 induction is a known off-target pharmacological property of the compound.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
90.8% positive response rate in 728 patients on 28-day course
Primary human efficacy data for bromantane; trial is not accessible in Western peer-reviewed literature. Figures are repeated across secondary nootropic and editorial sources, so treat the response rate as useful but not independently meta-analyzable.
1.3–1.6× improvement over amphetamine in exercise performance in mice and rats
Morozov & Kleimenova 1998. Animal data; human translation is extrapolation only.
More than twofold increase in TH mRNA after a single dose via CpG demethylation
Russian Ladasten mechanistic study cited in secondary editorial discussion. Key mechanistic finding supporting the enzyme-upregulation model.
Anxiolytic phenotype in BALB/c mice, stimulatory phenotype in C57B1/6 mice at same dose
Seredenin & Miramedova, Bulletin of Experimental Biology and Medicine 1999. Explains inter-individual response variability in humans via genetic phenotype variation.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.